Loading...
Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease.
Socinski, M Kaye, F Spigel, D Kudrik, F Ponce, S Ellis, P Majem, M Lorigan, Paul C Gandhi, L Gutierrez, M
Socinski, M
Kaye, F
Spigel, D
Kudrik, F
Ponce, S
Ellis, P
Majem, M
Lorigan, Paul C
Gandhi, L
Gutierrez, M
Citations
Altmetric:
Abstract
This trial assessed the safety and efficacy of LM in combination with carboplatin/etoposide therapy compared to carboplatin/etoposide treatment alone in patients with previously untreated extensive-disease small-cell lung cancer (ED-SCLC).
Description
Date
2017-01
Publisher
Collections
Files
Keywords
Type
Article
Citation
Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. 2017, 18(1):68-76.e2 Clin Lung Cancer